Vivani Medical (VANI) Return on Capital Employed (2018 - 2026)
Vivani Medical (VANI) posted quarterly Return on Capital Employed of 81.57% for Q1 2026, up 8591.0% year-over-year from 0.94% in Q1 2025, and up 24.16% quarter-over-quarter from 107.56% in Q4 2025.
Vivani Medical (VANI) Return on Capital Employed (2018 - 2026) Analysis & Trends
Vivani Medical's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 81.57% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 8591.0% year-over-year to 81.57%; the TTM figure through Mar 2026 stood at 81.57% (up 8591.0% YoY), while the FY2025 annual figure was 81.35%, down 1588.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 81.57%, up from 107.56% in the prior quarter.
- The five-year high for Return on Capital Employed was 19.8% in Q2 2022, with the low at 331.27% in Q2 2025.
- The 5-year median for Return on Capital Employed is 60.91% (2024), against an average of 84.07%.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed sank 27539 bps in 2025, then jumped 8591 bps in 2026.
- Vivani Medical's Return on Capital Employed stood at 44.92% in 2022, then slumped by 37 bps to 61.51% in 2023, then decreased by 11 bps to 68.09% in 2024, then tumbled by 58 bps to 107.56% in 2025, then grew by 24 bps to 81.57% in 2026.
- Business Quant data shows VANI's Return on Capital Employed at 81.57% in Q1 2026, 107.56% in Q4 2025, and 135.04% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | Vivani Medical | 122.80 Mn | 102.90 Mn | - | -77.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -77.05% |
| Mar 31, 2026 | -81.57% |
| Dec 31, 2025 | -107.56% |
| Sep 30, 2025 | -135.04% |
| Jun 30, 2025 | -331.27% |
| Mar 31, 2025 | -167.48% |
| Dec 31, 2024 | -68.09% |
| Sep 30, 2024 | -62.19% |
| Jun 30, 2024 | -55.88% |
| Mar 31, 2024 | -60.91% |
| Dec 31, 2023 | -61.51% |
| Sep 30, 2023 | -58.21% |
| Jun 30, 2023 | -59.63% |
| Mar 31, 2023 | -56.97% |
| Dec 31, 2022 | -44.92% |
| Sep 30, 2022 | -26.44% |
| Jun 30, 2022 | -19.80% |
| Mar 31, 2022 | -31.72% |
| Dec 31, 2021 | -26.47% |
| Sep 30, 2021 | -13.97% |